The treatments reduced the percentage of T cells co-expressing acetylcholine (Ach)IL-17A, AChIL-22, and AChRORγt while increasing the Foxp3-expressing T cells in PBMC from COPD patients [73]. Here, IL17A is linked to chronic obstructive pulmonary disease.